A5041512465- Viral gastroenteritis research and epidemiology
- Escherichia coli research studies
- Vibrio bacteria research studies
- Clostridium difficile and Clostridium perfringens research
- Viral Infections and Immunology Research
- Animal Virus Infections Studies
- Influenza Virus Research Studies
- Child Nutrition and Water Access
- Salmonella and Campylobacter epidemiology
International Vaccine Institute
2021-2025
Yonsei University
2024
In October, 2017, WHO launched a strategy to eliminate cholera by 2030. A primary challenge in meeting this goal is the limited global supply capacity of oral vaccine and worsening outbreaks since 2021. To help address current shortage vaccine, prequalified Euvichol-Plus was reformulated reducing number components inactivation methods. We aimed evaluate immunogenicity safety Euvichol-S (EuBiologics, Seoul, South Korea) compared with an active control Shanchol (Sanofi Healthcare India,...
Conjugate vaccine platform is a promising strategy to overcome the poor immunogenicity of bacterial polysaccharide antigens in infants and children. A carrier protein conjugate vaccines works not only as an immune stimulator polysaccharide, but also immunogen; with latter generally considered measured outcome real world. Here, we probed potential induce enhanced truncated rotavirus spike ΔVP8*. ΔVP8* was covalently conjugated Vi capsular (Vi) Salmonella Typhi develop bivalent vaccine, termed...
Immunity protective against shigella infection targets the bacterial O-specific polysaccharide (OSP) component of lipopolysaccharide. A multivalent vaccine would ideally target most common global Shigella species and serotypes such as flexneri 2a, S. 3a, 6, sonnei. We previously reported development conjugate vaccines (SCVs) targeting 2a (SCV-Sf2a) 3a (SCV-Sf3a) using a platform squaric acid chemistry conjugation approach carrier protein rTTHc, 52 kDa recombinant fragment heavy chain tetanus...
Background: To help address the current shortage of vaccine, a WHO prequalified bivalent whole cell (WC) OCV, Euvichol-Plus was reformulated by reducing number components and inactivation methods. Methods: The phase 3, observer-blind, randomized, active-controlled trial performed in healthy participants aged 1-40 years Nepal.Eligible were enrolled to receive two doses either Euvichol-S (Euvichol-Simplified, process-optimized monovalent WC OCV containing components) or an active control...